Asimadoline

DRUG7 trials

Sponsors

Tioga Pharmaceuticals, Mayo Clinic

Conditions

Atopic DermatitisDiarrhea Predominant Irritable Bowel SyndromeHealthyIrritable Bowel SyndromePost-Operative IleusPruritusVasomotor Symptoms

Phase 1

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

CompletedNCT01380561

Tioga PharmaceuticalsHealthy

Start: 2011-06-30End: 2011-07-31Updated: 2011-10-18

Phase 2

Asimadoline for the Treatment of Post-Operative Ileus

TerminatedNCT00443040

Tioga PharmaceuticalsPost-Operative Ileus

Start: 2007-01-31End: 2008-02-29Updated: 2012-01-06

Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome

CompletedNCT00454688

Tioga PharmaceuticalsIrritable Bowel Syndrome

Start: 2006-08-31End: 2007-12-31Updated: 2011-10-18

Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome

CompletedNCT00955994

Mayo ClinicIrritable Bowel Syndrome

Start: 2005-01-31End: 2007-03-31Target: 100Updated: 2011-03-23

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

CompletedNCT02475447

Tioga PharmaceuticalsAtopic Dermatitis, Pruritus

Start: 2015-07-31End: 2017-06-30Updated: 2017-12-13

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

RecruitingNCT07042516

Tioga PharmaceuticalsVasomotor Symptoms

Start: 2025-08-13End: 2027-02-20Target: 120Updated: 2025-09-09

Phase 3

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

CompletedNCT01100684

Tioga PharmaceuticalsDiarrhea Predominant Irritable Bowel Syndrome

Start: 2010-05-31End: 2013-06-30Updated: 2013-12-18